Literature DB >> 34303786

Micronutrients for Attention-Deficit/Hyperactivity Disorder in Youths: A Placebo-Controlled Randomized Clinical Trial.

Jeanette M Johnstone1, Irene Hatsu2, Gabriella Tost3, Priya Srikanth4, Leanna P Eiterman2, Alisha M Bruton3, Hayleigh K Ast3, Lisa M Robinette2, Madeline M Stern2, Elizabeth G Millington5, Barbara L Gracious6, Andrew J Hughes3, Brenda M Y Leung5, L Eugene Arnold2.   

Abstract

OBJECTIVE: To evaluate whether micronutrients (vitamins/minerals) benefit attention-deficit/hyperactivity disorder (ADHD) and irritability in a North American pediatric sample.
METHOD: A 3-site, 8-week, placebo-controlled, randomized clinical trial of micronutrients was conducted in nonmedicated children aged 6 to 12 years with ADHD and at least 1 impairing irritability symptom by parent report on the Child and Adolescent Symptom Inventory-5 (CASI-5). A priori-defined primary outcomes were Clinical Global Impression-Improvement (CGI-I) (CGI-I of 1 or 2 = treatment responder) and parent-rated CASI-5 composite score of ADHD, oppositional defiant, disruptive mood dysregulation, and peer conflict symptoms, including impairment scores.
RESULTS: Of 135 randomized (mean age 9.8 years), 126 youths (93%) comprised the modified intention-to-treat population. Blinding was maintained. For the CGI-I, 54% of the micronutrient and 18% of the placebo group were responders (risk ratio = 2.97, 97.5% CI = 1.50, 5.90, p < .001). CASI-5 composite scores improved significantly for both groups (p < .01), with a mean change of -0.31 (95% CI = -0.39, -0.23) in the micronutrient group and a mean change of -0.28 (95% CI = -0.38, -0.19) in the placebo group. However, the between-group difference was not significant (mean change = -0.02; 97.5% CI = -0.16, 0.12, effect size = 0.07, p = .70). The micronutrient group grew 6 mm more than the placebo group (p = .002). No serious adverse events or clinically significant changes from baseline in blood and urine tests occurred.
CONCLUSION: Micronutrients showed global benefit over placebo by blinded clinician rating, but not by parent-report CASI-5 composite rating in a population with ADHD and irritability. Micronutrients showed greater height growth. Micronutrients were well tolerated, and the majority of participants adhered to the number of capsules prescribed. This randomized controlled trial replicates safety and efficacy reported for ADHD in 2 smaller trials of a similar formula containing all vitamins and known essential minerals in amounts between the Recommended Dietary Allowance and Upper Tolerable Intake Level. CLINICAL TRIAL REGISTRATION INFORMATION: Micronutrients for ADHD in Youth (MADDY) Study; https://clinicaltrials.gov; NCT03252522.
Copyright © 2021 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  attention-deficit/hyperactivity disorder; dysregulated mood; irritability; micronutrients

Mesh:

Substances:

Year:  2021        PMID: 34303786      PMCID: PMC8782920          DOI: 10.1016/j.jaac.2021.07.005

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   13.113


  42 in total

1.  Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial.

Authors:  C Bernard Gesch; Sean M Hammond; Sarah E Hampson; Anita Eves; Martin J Crowder
Journal:  Br J Psychiatry       Date:  2002-07       Impact factor: 9.319

Review 2.  Assessing clients in their natural environments with electronic diaries: rationale, benefits, limitations, and barriers.

Authors:  Thomas M Piasecki; Michael R Hufford; Marika Solhan; Timothy J Trull
Journal:  Psychol Assess       Date:  2007-03

3.  A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants.

Authors:  James G Waxmonsky; William E Pelham; Adriana Campa; Daniel A Waschbusch; Tan Li; Rebecca Marshall; Lysett Babocsai; Hugh Humphery; Elizabeth Gnagy; James Swanson; Tomasz Hanć; Negar Fallahazad; William E Pelham
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-08-29       Impact factor: 8.829

4.  Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation.

Authors:  Jeanette M Johnstone; Brenda M Y Leung; Priya Srikanth; Irene Hatsu; Leanna Perez; Barbara Gracious; Gabriella Tost; Michael G Aman; Kenneth D Gadow; Robert L Findling; Oscar Bukstein; L Eugene Arnold
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-02-26       Impact factor: 2.576

Review 5.  Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

Authors:  Samuele Cortese; Martin Holtmann; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Ralf W Dittmann; John Graham; Eric Taylor; Joseph Sergeant
Journal:  J Child Psychol Psychiatry       Date:  2013-01-07       Impact factor: 8.982

6.  Attention-deficit/hyperactivity disorder and social skills in youth: a moderated mediation model of emotion dysregulation and depression.

Authors:  Nora Bunford; Steven W Evans; Stephen P Becker; Joshua M Langberg
Journal:  J Abnorm Child Psychol       Date:  2015-02

7.  Systematic review of safety and tolerability of a complex micronutrient formula used in mental health.

Authors:  J Steven A Simpson; Susan G Crawford; Estelle T Goldstein; Catherine Field; Ellen Burgess; Bonnie J Kaplan
Journal:  BMC Psychiatry       Date:  2011-04-18       Impact factor: 3.630

8.  Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA).

Authors:  Lorena Fernández de la Cruz; Emily Simonoff; James J McGough; Jeffrey M Halperin; L Eugene Arnold; Argyris Stringaris
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-10-18       Impact factor: 8.829

Review 9.  Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.

Authors:  Leonie Hennissen; Mireille J Bakker; Tobias Banaschewski; Sara Carucci; David Coghill; Marina Danckaerts; Ralf W Dittmann; Chris Hollis; Hanna Kovshoff; Suzanne McCarthy; Peter Nagy; Edmund Sonuga-Barke; Ian C K Wong; Alessandro Zuddas; Eric Rosenthal; Jan K Buitelaar
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

10.  Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes.

Authors:  Victoria Vickerstaff; Rumana Z Omar; Gareth Ambler
Journal:  BMC Med Res Methodol       Date:  2019-06-21       Impact factor: 4.615

View more
  2 in total

1.  Pain sensitivity and perceptual sensitivity are associated with severity of emotional dysregulation in children with ADHD: a cross-sectional analysis using the Temperament in Middle Childhood Questionnaire.

Authors:  Alisha M Bruton; Angela Senders; Gabriella Tost; Hayleigh Ast; Lisa M Robinette; Brenda Leung; Irene E Hatsu; L Eugene Arnold; Jeanette M Johnstone
Journal:  Disabil Rehabil       Date:  2022-03-10       Impact factor: 2.439

2.  Household Food Insecurity Is Associated with Symptoms of Emotional Dysregulation in Children with Attention Deficit Hyperactivity Disorder: The MADDY Study.

Authors:  Irene E Hatsu; Leanna Eiterman; Madeline Stern; Stacy Lu; Jeanette M Johnstone; Brenda M Y Leung; Priya Srikanth; Lisa Robinette; Gabriella Tost; James B Odei; Barbara L Gracious; L Eugene Arnold
Journal:  Nutrients       Date:  2022-03-20       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.